University Maastricht
Maastricht, Limburg, 6200 MD, Netherlands
NCT Number: NCT00468507
Patients undergoing major surgery, trauma and burns are prone to develop an exacerbated inflammatory response, which is potentially lethal to the individual. Recently our group demonstrated that administration of high fat feeding prior to hemorrhagic shock attenuates severe inflammation, gut barrier loss and hepatic damage. High fat feeding releases cholecystokinin in the gut, which stimulates the autonomous nervous system and subsequently activates the efferent vagus nerve. The activated efferent fibers inhibit tissue macrophages via binding of acetylcholine to the alpha7-nicotinergic receptor.
In this study the cholecystokinin release in healthy volunteers is monitored in response to low fat and high fat food products.
Looking for future studies?
Notify Me45 year–55 year
All sexes
Interventional
Early Phase 1
Maastricht, Limburg, 6200 MD, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Four nutritional interventions on four separate days per test person
Time frame: two hours
Looking for future studies?
Notify MeMaastricht University Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06334263
Spleen Injury, Trauma
Plymouth, Devon, United Kingdom
View Trial DetailsNCT06740409
Trauma, Wounds and Injuries
Baghdad, Iraq
View Trial DetailsNCT06705959
Trauma, Wounds and Injuries
Baghdad, Iraq
View Trial DetailsNCT05449834
Cardiovascular Diseases, Coagulopathy
Newcastle, New South Wales, Australia
View Trial Details